Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 16;11:809–821. doi: 10.2147/OTT.S151867

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Zhang et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

KLK11 silencing reversed the resistance to L-OHP and inhibited proliferation and activated apoptosis.

Notes: (A) Viability of HCT-8, HCT-8/L-OHP, CON, and KD2 cells treated with the indicated concentrations of L-OHP for 48 h. (B and D) The effect of L-OHP on apoptotic levels of the indicated cells analyzed by flow cytometry. (C) Proliferation levels of HCT-8, HCT-8/L-OHP, CON, and KD2 cells analyzed by MTT assay. Data are presented as mean ± SD of triplicate experiments. **P<0.01 versus HCT-8/L-OHP cell, and versus CON.

Abbreviations: KLK11, kallikrein11; L-OHP, oxaliplatin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; CON, control groups.